BridgeBio Pharma (BBIO) Return on Sales (2019 - 2026)

BridgeBio Pharma's Return on Sales history runs 8 years deep, the most recent figure standing at 0.01% for Q1 2026.

• In Q1 2026, Return on Sales changed 0.0% year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 0.01% (up 4.0% YoY), while the FY2025 annual figure was 0.01%, up 1.0% from the prior year.
• Return on Sales came in at 0.01% for Q1 2026 at BridgeBio Pharma, up from 0.01% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.0% in Q1 2024 to a low of 4.34% in Q3 2022.
• A 5-year average of 0.65% and a median of 0.43% in 2023 frame the typical range for Return on Sales.
• Across the five-year window, Return on Sales tumbled 365 bps in 2022 and jumped 391 bps in 2023, its largest moves.
• BridgeBio Pharma's Return on Sales stood at 0.78% in 2022, then slumped by 42 bps to 1.1% in 2023, then jumped by 59 bps to 0.45% in 2024, then surged by 97 bps to 0.01% in 2025, then soared by 54 bps to 0.01% in 2026.
• According to Business Quant data, Return on Sales over the past three periods registered 0.01%, 0.01%, and 0.02% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison